Skip to main content

ORIGINAL RESEARCH article

Front. Public Health
Sec. Infectious Diseases: Epidemiology and Prevention
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1425372

Clinical characteristics and severity markers in hospitalized COVID-19 patients from Western Mexico: A comparative analysis of Delta and Omicron variants

Provisionally accepted
Hazael R. Ceja Gálvez Hazael R. Ceja Gálvez 1Cristian O. Hernandez Ramirez Cristian O. Hernandez Ramirez 1Natali Vega-Magaña Natali Vega-Magaña 1JORGE HERNÁNDEZ-BELLO JORGE HERNÁNDEZ-BELLO 1Kevin J. Arellano Arteaga Kevin J. Arellano Arteaga 2Francisco J. Turrubiates Hernández Francisco J. Turrubiates Hernández 1Diana L. Padilla Borquez Diana L. Padilla Borquez 1José F. Muñoz-Valle José F. Muñoz-Valle 1*
  • 1 Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara., Guadalajara, Mexico
  • 2 Departamento de Medicina Interna, Civil Hospital of Guadalajara, Guadalajara, Jalisco, Mexico

The final, formatted version of the article will be published soon.

    Introduction: COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus notable for its rapid mutation rate, which has led to the emergence of various variants such as Delta and Omicron, each with potentially different levels of transmissibility and virulence. Therefore, this study aims to compare clinical charactheristics and markers associated with the severity of COVID-19 in hospitalized patients from western Mexico who were infected with the Delta and Omicron variants of SARS-CoV-2.This cross-sectional study involved 66 patients hospitalized for COVID-19, diagnosed by RT-qPCR. SARS-CoV-2 variants were identified through whole genome sequencing using the COVIDseq platform from Illumina. Upon admission, patients underwent a clinical history assessment, blood gas analysis, and blood biometry. Additionally, several tests and markers were measured, including the percentage of neutralizing antibodies, erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFα), D-dimer, lactate dehydrogenase (LDH), C-reactive protein (CRP) and ferritin.Results and Discussion: Patients hospitalized with the Omicron were found to be older, compared to those infected with the Delta (64 vs. 54 years, p = 0.006). Additionally, a higher proportion of male patients were observed in the Omicron compared to the Delta (p = 0.029). Both Omicron and Delta variants were associated with lymphopenia, although the lymphocyte count was lower in Omicron ( 0.9 vs. 0.56 10x 3 /L; p = 0.007). The COVID-GRAM scale indicated a high risk for severe disease in both groups, but the score was higher in Omicron compared to Delta (157 vs. 128 points; p = 0.0004). Patients infected with Omicron exhibited a lower percentage of neutralizing antibodies than those with Delta (35.99 vs. 81%; p < 0.05), regardless of their vaccination status. Among the markers assessed, globular ESR was found to be lower in Omicron compared to Delta (30.5 vs. 41.5 mm/h; p = 0.001), while ferritin levels were higher in patients infected with the Omicron (1359 vs. 960.6 µg/L; p = 0.007). In patients with severe COVID-19, markers such as lymphopenia, neutralizing antibody levels, ferritin, and COVID-GRAM scores are elevated in the Omicron variant, while only the leukocyte count and ESR for the Delta variant.

    Keywords: SARS-CoV-2, COVID-19, delta, omicron, Severity markers

    Received: 29 Apr 2024; Accepted: 12 Aug 2024.

    Copyright: © 2024 Ceja Gálvez, Hernandez Ramirez, Vega-Magaña, HERNÁNDEZ-BELLO, Arellano Arteaga, Turrubiates Hernández, Padilla Borquez and Muñoz-Valle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: José F. Muñoz-Valle, Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara., Guadalajara, Mexico

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.